WallStSmart

POMDOCTOR LIMITED American Depositary Shares (POM)vsScienture Holdings, Inc. (SCNX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

POMDOCTOR LIMITED American Depositary Shares generates 48592% more annual revenue ($399.92M vs $821,320). SCNX leads profitability with a 0.0% profit margin vs -53.2%. SCNX earns a higher WallStSmart Score of 33/100 (F).

POM

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -33.39

SCNX

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: 0.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for POM.

SCNXUndervalued (+61.0%)

Margin of Safety

+61.0%

Fair Value

$1.15

Current Price

$0.35

$0.80 discount

UndervaluedFair: $1.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

POM2 strengths · Avg: 9.0/10
Debt/EquityHealth
-1.0010/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
17.2%8/10

17.2% revenue growth

SCNX3 strengths · Avg: 9.7/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
449.1%10/10

Revenue surging 449.1% year-over-year

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

Areas to Watch

POM4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.19M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.32M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : POM

The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.

Bull Case : SCNX

The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.

Bear Case : POM

The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

POM profiles as a growth stock while SCNX is a hypergrowth play — different risk/reward profiles.

SCNX is growing revenue faster at 449.1% — sustainability is the question.

SCNX generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SCNX scores higher overall (33/100 vs 28/100) and 449.1% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

POMDOCTOR LIMITED American Depositary Shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.

Visit Website →

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.

Want to dig deeper into these stocks?